Axsome Therapeutics (AXSM) Misses Q2 EPS by 30c
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Join SI Premium – FREE
Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $46.01 million versus the consensus estimate of $40.89 million.
For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital
- Integra Resources (ITRG) Tops Q2 EPS by 6c
- Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
